Halozyme Therapeutics
Price & Volume
Stats
See moreOpen | $71.51 |
Previous Close | $71.67 |
Day Range | $71.38-$72.59 |
52W Range | $47.50-$79.50 |
Market Cap | $8.4B |
Shares Short | 13M |
Financials
See moreRevenue (12 Mos) | $1.2B |
Revenue Growth (YoY) | 22.1% |
Gross Profit (12 Mos) | $980.7M |
Diluted EPS | $4.74 |
News
See moreYahoo Finance • 14 days ago
Here’s What Analysts Think About Halozyme Therapeutics (HALO)
Yahoo Finance • 26 days ago
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
Yahoo Finance • 27 days ago
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
Yahoo Finance • last month
Toast upgraded, PayPal downgraded: Wall Street’s top analyst calls
About
CEO | Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. |
Address | 12390 El Camino Real, San Diego, CA, United States, 92130 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 350 |
